Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Oenocarpus bataua vegetable oil may help reduce hair loss by affecting a key gene pathway.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

This study demonstrated higher STAT3 gene expression in scalp tissue affected by androgenetic alopecia, but found no significant link with hair loss severity.

This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3.

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

This study found that long noncoding RNA profiles in Wan strain Angora rabbits may help understand the molecular mechanisms regulating hair follicle density, potentially influencing wool fiber production.

This review highlights the potential of natural compounds like terpenoids, flavonoids, and polyphenols in promoting hair regrowth for those with alopecia areata by activating growth pathways and modulating immune responses, but calls for further research to confirm their therapeutic utility.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This review summarizes recent research on alopecia areata, highlighting advances in targeted therapies due to improved understanding of its immunopathogenesis, though it reports no new clinical results.

This review discusses the JAK/STAT signaling pathway's role in immune-mediated skin diseases and examines the efficacy and safety of JAK inhibitors for treating vitiligo and alopecia areata, but reports no new clinical results.

In this study, topical naringin was found to significantly improve dermatitis severity and reduce inflammatory markers in a mouse model of atopic dermatitis, suggesting its potential as a therapeutic agent for this condition.

This study found that a specific macrophage subpopulation in the dermis helps maintain hair follicle stem cell quiescence through cytokine-mediated signaling.

This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

Blocking the JAK/STAT pathway may help reduce skin sensitivity in Xeroderma pigmentosum.

This report details a six-month internship experience, split between hospital and community pharmacy settings, which enhanced practical skills and theoretical knowledge in pharmaceutical care and highlighted the pharmacist's role in ensuring safe medication use.

This study found that CXCL12 inhibits hair growth via the CXCR4/STAT signaling pathway, suggesting that targeting this pathway could be a promising approach for promoting hair growth.

This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This review suggests that novel treatment developments targeting the pathomechanics of alopecia areata, such as JAK inhibitors, show promise, although optimal treatment strategies are still under investigation.

This review discusses recent findings on the efficacy of JAK inhibitors for treating alopecia areata, highlighting their role in reversing hair loss by targeting the JAK-STAT signaling pathway, though questions about their effectiveness and safety remain.

In this case report, a 24-year-old woman with Down syndrome effectively managed coexisting alopecia areata and hidradenitis suppurativa using upadacitinib, following partial success with previous treatments.

This study found that black phosphorus nanosheets positively influence skin repair by enhancing angiogenesis, anti-inflammatory response, collagen deposition, and re-epithelialization in a rat model of skin wounds, potentially through activating the JAK-STAT-OAS signaling pathway.